Waf1/Cip1 is a p53 transcription target implicated in both major functions of the tumor suppressor-cell cycle arrest and apoptosis. It is a potent inhibitor of the key cyclindependent kinases (CDK1-4), and has been thought to be the main mediator of p53-dependent G1 and G2 arrest. However, an increasing body of information suggests that in addition to its cell-cycle inhibitory activity, p21 can affect p53-dependent apoptosis. These data have been obtained from experiments in which p53 is activated primarily by genotoxic stress. In this study, we use the selective MDM2 antagonist, nutlin-3a, as a nongenotoxic p53 activator and show that the cell-cycle arrest function of p21 is dependent on the cellular context. In most cancer cell lines, p53-dependent p21 induction is essential for cellcycle arrest, but in some, p21 is dispensable. Depletion of p21 did not increase the apoptotic response to nutlin-3a in all seven cancer cell lines tested and p21 overexpression did not protect apoptosis-sensitive lines from death. p21 was found to mediate nutlin-induced p53-dependent downregulation of another antiapoptotic protein, survivin, without significantly affecting the apoptotic outcome. Taken together our results suggest that p21 induction does not affect the apoptotic response to nongenotoxic p53 activation.
Introduction
The tumor-suppressor p53 is a potent transcription factor, which is activated in response to diverse forms of oncogenic stress and induces cell-cycle arrest, apoptosis or senescence to protect us from cancer . p53 protein accumulates in cell nuclei by a posttranslational mechanism and activates multiple target genes that mediate its tumor suppressor functions (Harris and Levine, 2005) . One of these genes, p21
Waf1/Cip1 (el-Deiry et al., 1993 , Harper et al., 1993 , a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors, binds and inhibits the activity of cyclin/CDK complexes (for example, CDK1, 2 and 4), thus effectively blocking cell-cycle progression (Xiong et al., 1993) . Forced expression of p21 has been shown to arrest the cell cycle at the G1/S or G2/M phase border (Bunz et al., 1999 , Dulic et al., 1998 . As a cell-cycle inhibitor, p21 has been assigned a major role in the growth arrest after DNA damage and is thought to be a key mediator of p53 tumor suppressor function (Xiong et al., 1993; Bunz et al., 1999) . Although p21 is a transcription target of p53 and its expression is mainly regulated by the tumor suppressor, p53-independent mechanisms have also been described in response to variety of stresses including DNA damage (Gartel and Tyner, 1999) .
In addition to its cell-cycle inhibitor function, p21 has been reported to affect either negatively or positively another major p53 function, induction of apoptosis (Abbas and Dutta, 2009) . In response to DNA damage and subsequent p53 activation, cells can either undergo cell-cycle arrest or apoptosis depending on the extend of damage and other still unknown factors (Vousden and Lu, 2002) . Although the mechanisms underlying this life or death decision remain mostly elusive, p21 has been suggested to have a role by inhibiting apoptosis (Gartel and Tyner, 2002; Janicke et al., 2007) . HCT116 human colon carcinoma cells have been shown to undergo cellcycle arrest following DNA damage in the presence of doxorubicin, but their p21-null variant undergoes apoptosis (Bunz et al., 1999; Chan et al., 2000) . Similarly, p21-specific antisense oligonucleotides increase the sensitivity of HCT116 cells to chemo-and radiotherapy in vitro and HCT116 tumor xenografts in nude mice (Tian et al., 2000) . Other experiments have suggested that repression of p21 transcription or defects in p53-dependent induction of p21 may also lead to increased apoptosis. The c-myc oncogene can switch p53-dependent response to DNA damage from cell-cycle arrest to apoptosis by inhibiting p21 transactivation (Seoane et al., 2002) . Similarly, p53 point mutants unable to transactivate p21 have been found to be more potent inducers of apoptosis than wild-type p53 (Bissonnette and Hunting, 1998; Kokontis et al., 2001 ).
The proposed mechanisms by which p21 could protect cancer cells from apoptosis include direct binding to procaspase-3 and blocking its activation (Suzuki et al., 1998) , inhibition of apoptosis signal-regulating kinase 1 (Asada et al., 1999; Huang et al., 2003) , inhibition of CDKs required for the apoptotic process (Lu et al., 1998; Sohn et al., 2006) and regulation of gene expression through direct interaction with several transcription factors and cofactors (Perkins 2002) . Furthermore, caspase-3-mediated cleavage of p21 has also been reported to contribute to the antiapoptotic activity of p21 (Levkau et al., 1998; Zhang et al., 1999) . The bulk of data in support of the proposed antiapoptotic role of p21 has been derived from experiments in which p53 is induced by genotoxic insults. However, p53 response to genotoxic agents is known to involve multiple mechanisms, both p53-dependent and p53-independent. Therefore, it is of interest to know if p21 induced by nongenotoxic activation of the p53 pathway has a role in the apoptotic outcome.
Given its powerful growth suppressive and proapoptotic potential, p53 activation has been considered an attractive therapeutic strategy in cancer (Brown et al., 2009) . One p53 activation strategy targets the interaction of p53 with its negative regulator MDM2 (Vassilev 2007) . Recently developed small-molecule p53-MDM2 binding inhibitors, the nutlins, stabilize p53 and activate the p53 pathway only in cells with wild-type but not mutant p53 (Vassilev et al., 2004) . They are highly selective to their target in cells, and thus provide a unique tool to study the activation of the p53 pathway without DNA damage or other stress-induced signaling events (Thompson et al., 2004; Tovar et al., 2006) . In this study, we use the MDM2 antagonist, nutlin-3a, to investigate the role of p21 in cell-cycle arrest and apoptosis induced by nongenotoxic p53 activation. We find that although p21 is highly upregulated following nutlin-induced p53 accumulation, it does not affect p53-dependent apoptosis. Furthermore, whereas the growth inhibitory function of p21 is preserved in most tumor cell lines, p21 is dispensable for p53-dependent cell-cycle arrest in some cell lines. Our data suggest that p21 induced by pharmacological p53 activation, unlike stress-induced p53 activation, is not antiapoptotic.
Results

Dependency of p53-induced cell-cycle arrest on p21
Nutlin-3 is a potent and selective small molecule that binds MDM2 in the p53-binding pocket, thus preventing p53 degradation, leading to stabilization and activation of the tumor suppressor (Vassilev et al., 2004) . Nutlin treatment of cancer cells effectively activates both main functions of p53, cell-cycle arrest and apoptosis. We have shown previously that p53-dependent apoptosis is compromised in many cancer cell lines, but cell-cycle arrest function of p53 is preserved in all tested tumor-derived cell lines expressing wild-type p53 (Tovar et al., 2006; Xia et al., 2008) . The immediate downstream p53 target, p21, has been thought to be the main mediator of p53-dependent cell-cycle arrest (elDeiry et al., 1993; Bunz et al., 1999) . To examine the role of p21 in nutlin-induced cell-cycle block, we chose three tumor cell lines expressing wild-type p53, the colon cancer RKO and HCT116 cells, and SJSA1 osteosarcoma. These cell lines were primarily selected to cover the spectrum of apoptotic sensitivity to nutlin-3a: resistant (HCT116), partially sensitive (RKO) and highly sensitive (SJSA1) (Tovar et al., 2006) . Incubation of exponentially growing cells with the active enantiomer, nutlin-3a, for 24 h led to accumulation of p53 protein and induction of p21 mRNA and protein (Figures 1a  and c) . This was accompanied by upregulation of another p53 target, MDM2, in all three cell lines (Figure 1c) . The inactive enantiomer, nutlin-3b, which is approximately 200-fold less potent in binding to MDM2, was used as a negative control. Although p21 induction compared with controls was in close range between the cell lines (four to five fold), the relative mRNA levels varied approximately three fold (Figure 1a) . Consistent with our previous data (Tovar et al., 2006) , all three cell lines were effectively arrested in G1 and G2/M phase ( Figure 1d ). As previously reported (Thompson et al., 2004 ) nutlin treatment did not induce Ser15 phosphorylation on p53, confirming its nongenotoxic mechanism of p53 activation (Supplementary Figure 1 ).
We then used RNA interference to inhibit p21 expression. Our p21-specific small interfering RNAs (siRNAs) effectively reduced both the basal and induced mRNA levels greater than 85% of the control levels in RKO and 490% in HCT116 and SJSA cells (Figure 1b) . Western analysis showed that p21 protein levels are below the control uninduced level of the protein in the presence of nutlin-3a in all three lines (Figure 1c) . Depletion of p21 either completely (RKO) or partially (HCT116) restored cell-cycle progression, suggesting that p21 is required for nutlin-induced p53-dependent cell-cycle arrest in these lines. However, knockdown of p21 in SJSA cells did not release them from the cell-cycle block (Figure 1d ), indicating that p21 is dispensable for nutlin-induced cell-cycle arrest in these cells. p21 does not affect the apoptotic outcome of nutlin-induced p53 activation In contrast to cell-cycle arrest, tumor cell lines with wildtype p53 have shown a wide range of sensitivity to nutlin-induced apoptosis (Tovar et al., 2006) . HCT116 has been found to be resistant, whereas SJSA is highly sensitive and RKO has shown intermediate apoptotic index. As p21 is universally upregulated on p53 activation by nutlin, it may influence the apoptotic response as previously shown in experiments with genotoxic agents (Gartel and Tyner, 2002; Janicke et al., 2007) . Because of the different dependency on p21 for cell-cycle arrest, the selected cancer cell lines also offer the opportunity to test the hypothesis that cellcycle state can affect p53-dependent apoptotic response. RKO cells, in particular, represent a good model as depending on the presence or absence of p21, they can be either completely arrested in G1 and G2 phase or actively cycling in the presence of the same nutlin concentration. Thus, one can distinguish the direct effect of p21 on apoptosis from the indirect effect of p21-induced cell-cycle arrest. To this end, RKO, HCT116 and SJSA cells were first depleted of endogenous p21 by p21 and nutlin-induced apoptosis M Xia et al siRNA and then exposed to nutlin-3a for 24 or 48 h (in the apoptosis-sensitive SJSA cells) or up to 96 h in RKO and HCT116 cells. The fraction of dead/apoptotic cells was measured using the Annexin V and poly (ADPribose) polymerase (PARP) cleavage assays. Using both methods, we were unable to detect any signs of enhanced cell death (Figures 2a and b) . Instead, the Annexin V assay registered a slight, but consistent decrease in the apoptotic cell fraction in all three lines in the absence of p21 (Figure 2a) . In RKO and HCT116, the apoptotic fraction remained low from 24 to 96 h of treatment ( Figure 2a ). Another indicator of apoptosis, PARP, showed similar degree of cleavage in the presence of p21 siRNA compared with the nontargeting control siRNA (Figure 2b ) at all time points of exposure to nutlin-3a. Doxorubicin (1 mM), used as a positive control, produced a pronounced PARP cleavage in both RKO and HCT116 cells (Figure 2b ). Propidium iodide staining and fluorescence-activated cell sorting analysis revealed that the percentage of subG1 fraction remained unaltered on p21 depletion (data not shown). Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) experiments yielded comparable positivity in SJSA1 and slightly reduced terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive fraction in HCT116 and RKO cells (data not shown). To minimize the possibility for offtarget siRNA effects, key experiments were repeated using an independent siRNA from Santa Cruz Biotechnology (Santa Cruz, CA, USA), as well as p21-specific small hairpin RNA and the results were identical (Supplementary Figure 2) .
We then tested if exogenous p21 could block the p53-dependent apoptotic response induced by nutlin. Fulllength human p21 was transiently expressed in SJSA cells and nutlin-3a was added for 48 h. Western analysis showed substantial elevation of the basal p21 levels in the cells transfected with p21 expression construct compared with the vector controls ( Figure 2c ). Total p21 protein levels were further increased in the presence of nutlin-3a. However, no significant changes in the apoptotic fraction were registered by the Annexin V or PARP cleavage assays ( Figure 2d ).
We expanded our cell panel by including additional four solid tumor-derived cell lines: A549 and H460 (lung cancer), MCF7 (breast) cancer and MHM (osteosarcoma). These tumor cell lines had shown low (A549, H460), intermediate (MCF7) and high (MHM) apoptotic index in response to nutlin-3a (Tovar et al., 2006) . The activation of the p53 pathway by nutlin-3a was confirmed by the accumulation of p53, MDM2 and p21 proteins ( Figure 3a) . The p21-specific siRNA effectively depleted p21, bringing the nutlin-induced protein levels Figure 3a ). Depletion of p21 followed by 48 h of exposure to nutlin-3a did not significantly alter the apoptotic response in any of these cells, confirming that p21 does not have apoptosis-inhibitory function on p53 activation by nutlin. Taken together, our data derived using multiple cancer cell lines and alternative siRNA species does not support an antiapoptotic role of p21 in the response to p53-dependent apoptosis induced by nutlin-3 in these lines.
Elevated p21 protects cancer cells from doxorubicin-induced apoptosis
We next checked whether p21 can have an antiapoptotic role in the response to DNA damage as previously reported (Bunz et al., 1999; Tian et al., 2000; Gartel and Tyner, 2002) . We chose the genotoxic drug, doxorubicin, frequently used to activate the p53 response.
Treatment of RKO and HCT116 cells with 300 nM doxorubicin gave rise to a moderate fraction of apoptotic cells. Targeted p21 siRNA dramatically elevated the apoptotic rate revealed by the increase of subG1 cell fraction from 17 to 52% in RKO and 9 to 37% in HCT116 cells (Figure 4a ). Western analysis showed a drop in full-length PARP and reciprocal increase in cleaved PARP in the higher apoptotic fraction (Figure 4b ). These results indicate that p21 can function as an inhibitor of apoptosis induced in response to DNA damage as previously reported by others.
p21 mediates survivin downregulation in response to nutlin-3a Disruption of the p53-MDM2 interaction by nutlin leads to stabilization and activation of p53, followed by profound changes in gene expression (Tovar et al., . One of the most prominently downregulated genes was BIRC5 encoding the survivin protein (Tovar et al., 2006) . Survivin is a member of the inhibitors of apoptosis protein family frequently found overexpressed in human cancer (Altieri 2003) . Owing to its antiapoptotic activity, survivin overexpression has been thought to have an important role in tumor development, although the precise molecular mechanisms have not Figure 4 p21 protects cancer cells from doxorubicin-induced apoptosis in RKO and HCT116. RKO and HCT116 were transfected with p21 siRNA or control siRNA for 24 h and 300 nM doxorubicin or DMSO solvent were added for additional 96 h. The effect of p21 knockdown on apoptosis was detected by the increase of subG1 cell fraction measured by flow cytometry (a) or appearance of cleaved PARP by western analysis (b).
p21 and nutlin-induced apoptosis M Xia et al been elucidated (Altieri, 2008) . Treatment of RKO and SJSA cells with nutlin-3a for 24 h led to a strong inhibition of survivin expression (Figure 5a ). However, as survivin expression is cell cycle dependent with the bulk of mRNA accumulating in cells before entry into mitosis (Li et al., 1998) , this suppression could result from cell-cycle arrest in G1 and G2 phase after nutlin treatment ( Figure 5 p21 mediates the suppression of survivin expression in response to nutlin-3a. RKO and SJSA cells were transfected with p21 siRNA or control siRNA for 24 h. Nutlin-3a (10 mM) was added to the culture 24 h later and cells were collected for qPCR analysis of survivin and p21 mRNA (a) and western blotting (b). Expression levels of mRNA were normalized to siRNA controls. (c) H1299 cells were stably transfected with pReceiver-p21 or control plasmid and G418-resistant cells were pooled. Survivin and p21 mRNA were measured by qPCR and expressed as relative levels normalized to vector-transfected controls. (d) H1299 cells were incubated with 1 mM doxorubicin or equivalent DMSO solvent (NTC) for 24 h before qRCR analysis and expressed as relative values normalized to notreatment controls. (e) Survivin protein levels in the p21-overexpressing or doxorubicin-treated H1299 cells were analyzed by western blotting. (f) SJSA and MHM cells were transfected with human full-length survivin expression plasmid or vector control (pEZ-M02 from GeneCopoeia) for 24 h and then treated with 10 mM nutlin-3a for additional 24 h. The expression of survivin was analyzed by western blotting. (g) Cells were transfected as in (f) and then incubated with nutlin-3a for 48 h. Apoptosis was measured by the Annexin V assay.
p21 and nutlin-induced apoptosis M Xia et al progression. Therefore, RKO cells offered a model for testing the role of nutlin-induced p53 activation on survivin expression in both asynchronous and G1-and G2-arrested cells. Knockdown of p21 restored most of the lost survivin expression in both SJSA and RKO cells, suggesting that survivin downregulation is not a consequence of nutlin-induced cell-cycle block, but mediated by cell-cycle-independent activity of p21 (Figures 5a and b ). Next, we tested if ectopic expression of p21 in the absence of p53 is sufficient for suppression of survivin. To this end, p21 was overexpressed in the p53-null H1299 lung cancer cell line. The cellular levels of p21 measured 24 h after transfection ( Figure 5c ) were comparable to the levels produced by nutlin-induced p53 activation in RKO cells (Figure 5a ) and other cancer cells lines (Tovar et al., 2006) . However, the survivin mRNA and protein levels remained the same as in the control vector-transfected cells (Figures 5c and e) . It has been shown that p21 expression is not entirely p53-dependent and can be induced in p53-null or mutant cancer cells in response to genotoxic stress (Gartel and Tyner, 1999; Yang et al., 2003) , Therefore, we used the genotoxic drug doxorubicin to upregulate p21. Treatment of H1299 cells with 1 mM doxorubicin resulted in p53-independent upregulation of p21 transcription ( Figure 5d ) and protein levels (data not shown). However, the survivin expression remained at comparable levels as in the no-drug control cells (Figures 5d and e) . These experiments suggest that enhanced expression of p21 alone is insufficient to suppress survivin transcription that requires concomitant p53 activation.
Owing to the potential antiapoptotic role of survivin, we asked whether overexpression of exogenous survivin would protect cancer cells from nutlin-induced apoptosis. SJSA and MHM cells were transfected with the survivin-expression plasmids and survivin protein was analyzed by western blotting. Despite the massive increase in survivin protein levels, sensitivity of both cell lines to nutlin-induced apoptosis remained unchanged (Figures 5f and g ). These results suggest that survivin is unlikely to have an antiapoptotic role and its downregulation by MDM2 antagonists does not affect the apoptotic response.
Discussion
Since its discovery as the first p53-regulated gene (Harper et al., 1993; el-Deiry et al., 1993) , p21 has been extensively studied and its important role in p53-mediated tumor suppression as a potent cell-cycle inhibitor has been well documented (Bunz et al., 1999; Harris and Levine, 2005) . However, the proposed p21 functions outside the cell cycle are poorly defined and somewhat controversial. A number of studies have presented evidence that p21 can protect cells from apoptosis induced by genotoxic insults or chemotherapeutics both in vitro and in animal models (Gartel and Tyner, 2002; Abbas and Dutta, 2009) . Most of these studies have used DNA damage to activate p53 that is known to induce both p53-dependent and p53-independent signaling events, making the data difficult to interpret and sometimes confusing. In this study, we use the p53-MDM2 binding inhibitor, nutlin-3, to selectively activate p53 without DNA damage and investigate the role of p21 in cell-cycle arrest and apoptosis in multiple cancer cell lines. We find that the cell-cycle arrest function of p21 depends on the cellular context. p21 induction by p53 is essential for cell-cycle arrest in the colon cancer lines, RKO and HCT116. However, p21 is completely dispensable for cell-cycle arrest in the osteosarcoma cell line SJSA1. The reasons behind p21 independency are not clear yet, but one can speculate that other p53-dependent cell-cycle regulators can substitute for p21 to assure effective cell-cycle arrest. Three possible players (SFN, Gadd45A and BTG2) were investigated, but no evidence for role in p21-independent cell-cycle arrest was found (data not shown).
Interestingly, nutlin-induced apoptotic response was independent of p21 upregulation by p53 in all seven cancer lines tested in this study. These results strongly suggest that p21 does not have an important role in modulating the apoptotic response to nongenotoxic p53 activation. This conclusion can be extended to the cellcycle state as an alleged modulator of the apoptotic response. By depleting p21, we generated a population of RKO cells that can proliferate in the presence of nutlin-induced p53 with rates identical to untreated controls. Careful comparison of the apoptotic rate in these p21 knockdown cells and p21 'normal' RKO cells blocked in G1 and G2 phase in the presence of the same nutlin concentration did not reveal any differences. These results clearly indicate that cell-cycle arrest does not affect the apoptotic response to nongenotoxic p53 activation. In contrast, ablation of p21 by siRNA in the colon cancer lines RKO and HCT116, sensitized these cells to doxorubicin, confirming previous observations that p21 can function as an apoptosis modulator in the response to genotoxic stress.
We found that the induction of p21 by nutlin-3a, strongly suppresses the expression of survivin that has been shown to act as an inhibitor of apoptosis. It has been reported previously that the survivin gene can be inhibited transcriptionally by wild-type p53 protein that binds in its promoter region and recruits a repressor complex (Hoffman et al., 2002) . However, later studies have not confirmed the direct binding of p53 to the survivin promoter (Lohr et al., 2003) . Furthermore, they provided experimental evidence that p21 functions as a mediator of survivin suppression (Lohr et al., 2003) . Our results are consistent with a critical role of p21 in mediating negative regulation of survivin expression by p53. However, we do not find significant effect of ectopic p21 expression on survivin transcription in the absence of p53, suggesting that p53 expression/activation is necessary for the observed inhibitory effect. The molecular mechanism of survivin suppression by p21/p53 needs further investigation. The fact that p21 p21 and nutlin-induced apoptosis M Xia et al induction by nutlin leads to downregulation of a known antiapoptotic protein also argues against antiapoptotic role of p21 in the response to nongenotoxic p53 activation. However, besides SJSA and RKO cells, we have observed strong downregulation of survivin by nutlin-3a in several other cancer cell lines, but no correlation between the expression of survivin and their apoptotic index (data not shown). Our experiments directly addressing the role of survivin in SJSA and MHM cells also did not show any apoptosis-inhibitory effect (Figures 5f and g ). The role of survivin in modulation of apoptosis seems to be much more complex than initially thought. Its ability to antagonize cell death relies on multiple factors such as mitochondrial localization, phosphorylation status and physical interaction with other cofactors (Dohi et al., 2004 (Dohi et al., , 2007 Qi et al., 2009) . In fact, studies using RNA interference to deplete survivin have not been able to show a substantial effect on apoptosis (Carvalho et al., 2003; Lens et al., 2003) . Our results also do not support an antiapoptotic role of survivin in p53-dependent apoptosis induced by MDM2 antagonists.
A recent study published in the course of this study has reported that p21 downregulation by siRNA enhances the apoptotic response to nutlin-3 (Enge et al., 2009 ). This conclusion was based on limited experiments with a single cell line, HCT116. Our results using multiple cancer cell lines (including HCT116) and readouts do not support such a conclusion. In contrast, we were not able to find a single cellular system in which elevation of p21 levels have a significant role in the apoptotic response to nutlin.
Although a substantial number of reports claim an antiapoptotic role of p21 in the p53 pathway, many of these studies have used as a model system HCT116 (p21À/À) cells, generated by homologous disruption of the p21 gene (Bunz et al., 1999) . A recent study on the role of p21 in the response to Imatinib have shown that the hypersensitivity of HCT116 (p21À/À) cells is p53-dependent but p21-independent (Ferrandiz et al., 2009). Ferrandiz et al. have demonstrated that inducible p21 expression in HCT116 (p21À/À) cannot rescue the hypersensitivity of these cells to the tyrosine kinase inhibitor. In addition, downregulation of p21 expression by RNA interference or by forced expression of c-myc did not sensitize parental HCT116 cells. These observations suggest that the role of p21 in apoptosis should be reexamined using additional cellular models.
Our results that p21 does not inhibit the apoptotic response to nongenotoxic p53 activation have important implications for the development of MDM2 antagonists and other modalities directly targeting p53 for activation. As p21 is universally upregulated by activated p53, its inhibitory role will be detrimental to achieving effective therapeutic response in any cancer expressing wild-type p53. Our previous results suggested that this is an unlikely reason for lack of apoptotic response (Tovar et al., 2006) . Despite the fact that some cancer cell lines have shown minimal apoptosis in response to p53 activation by nutlin, there are cancer cell lines in which nutlin induces robust apoptotic response and there is no correlation between p21 induction and response (Tovar et al., 2006) . This study presents direct evidence that p21 does not have a role in the switch from cell-cycle arrest to apoptosis induced by selective nongenotoxic p53 activation. In fact, the cell line with the strongest apoptotic response, SJSA, has the most pronounced cell-cycle arrest that persists even in the absence of p21 (Figure 1d ). The molecular determinants of apoptotic response may differ between tumor types and stages, and there are likely multiple ways cancer cells can use to disable p53 downstream signaling. However, p21 does not seem to be a factor in the resistance to selective nongenotoxic p53 activation.
Materials and methods
Cells, constructs and drug treatment MHM osteosarcoma cells were provided by the Norwegian Radium Hospital, Oslo, Norway. All other cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in the recommended media supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA) in a humidified incubator with 5% CO 2 . Human p21-expressing construct, pReceiver-p21, was purchased from GeneCopoeia, Rockville, MD, USA. Nutlin-3a and 3b were synthesized at Hoffmann-La Roche, Nutley, NJ, USA. Doxorubicin was purchased from Sigma (St Louis, MO, USA). Drugs were dissolved in dimethyl sulfoxide and kept at À20 1C as 10 mM stock solutions.
Immunoblotting Cells were grown in 75 cm 2 flasks (10 6 cells per flasks) or 6-well plates (2 Â 105 cells per well), lysed in 0.1-0.2 ml RIPA buffer, and western blotting was performed as previously described (Tovar et al., 2006) . Primary antibodies used are as follows: mouse monoclonal anti-p53 (sc-263) and mouse monoclonal anti-MDM2 (sc-965) were from Santa Cruz Biotechnology, mouse monoclonal anti-p21 (OP64) from Calbiochem (Gibbstown, NJ, USA), rabbit polyclonal anti-PARP from Cell Signaling (Danvers, MA, USA) (9542), rabbit polyclonal anti-survivin (NB500-201) from Novus Biologicals (Littleton, CO, USA) and b-actin (AC-74) from Sigma. The secondary antibodies, anti-mouse IgG-HRP (sc-2302) and anti-rabbit IgG-HRP (sc-2301) were from Santa Cruz Biotechnology.
siRNA experiments Cells were seeded in 6-well plates at 50-60% confluence and transfected with 100 nM siRNAs using Lipofectamine 2000 (Invitrogen). The two human p21 siRNAs were from Dharmacon, Chicago, IL, USA (sense: 5 0 -GAUGGAACUUC GACUUUGUUU-3 0 ; antisense: 5 0 -ACAAAGUCGAAGUU CCAUCUU-3 0 ) or Santa Cruz Biotechnology (A pool of two target-specific siRNAs) respectively. After 24 h incubation with lipofectamine/siRNA mix, the medium was replaced with 3 ml fresh medium containing appropriate concentrations of drugs and incubated for additional time intervals as described. Cells were then collected and processed for western blot, Quantitative RT-PCR and apoptosis analysis as previously described (Xia et al., 2008) . For small hairpin RNA infection, cells were seeded in 6-well plates at 50-60% confluence and infected with SMARTvector shRNA-p21 lentiviral particles (Dharmacon) at multiplicity of infection 10. At 48 h postinfection, the cells were selected with 5 mg/ml puromycin. Quantitative RT-PCR Cells were seeded in 6-well plates and total RNA was isolated using RNeasy kit (Qiagen, Valencia, CA, USA). cDNA was synthesized from 4 mg of total RNA from each sample using Superscript II reverse transcriptase (Applied Biosystems, Foster City, CA, USA) according to manufacturer's protocol. The relative mRNA levels of the human p21 were determined by Taqman, using gene-specific primer/probe sets and 18S RNA as a normalization control. The sequence of the human p21 primers and probe were as follows: forward: 5 0 -CTGGA-GACTCTCAGGGTCGAA-3 0 ; reverse: 3 0 -CGGCGTTTGGA GTGGTAGAA-5 0 ; probe: 5 0 -TTGGCTCACTGCAAGCTCG CCCTT-3 0 . The survivin Taqman gene expression assay was purchased from Applied Biosystems.
Annexin V assay
Cells were seeded in 6-well tissue culture plates the night before siRNA transfections. At 24 h post-siRNA addition, the cells were treated with nutlin-3b or 3a for additional 24-96 h. Culture media were collected and combined with the trypsinized-attached cells. Cell pellets were collected by centrifugation at 2000 r.p.m. for 10 min at 4 1C. The percentage of apoptotic cells was determined by Annexin V/7-AAD staining using the Guava Nexin kit and the Guava personal cell analyzer (Guava Technologies, Hayward, CA, USA), and calculated as the total fraction Annexin V-positive cells as described (Thompson et al., 2004) .
Cell-cycle analysis
Changes in cell-cycle distrubution were assessed by flow cytometry. Cells were collected and fixed in 70% ethanol at À20 1C for 1 h and kept frozen. After thawing, cells were washed twice in cold phosphate-buffered saline and resuspended in 0.5 ml PI/RNase staining buffer (BD Pharmingen, San Diego, CA, USA), incubated for 15 min at 37 1C and analyzed using FACSCalibur cytometer (Becton Dickson, Franklin Lakes, NJ, USA) using CellQuest software (BD Biosciences, San Jose, CA, USA). In total, 20 mM BrdU (Sigma) was added 1 h before collecting the cells. Cells were fixed in 70% ethanol, permeablized with 2N HCl and 0.5% TritonX-100 for 30 min at room temperature, and neutralized with 0.1 M sodium tetraborate (pH 8.5). After washing, cells were labeled with anti-BrdU FITC-conjugated antibody (Becton Dickinson) in 0.5% Tween 20/phosphate-buffered saline for 1 h before analysis.
